Scholarlink

<p>Multimodal agonists targeting GLP-1, GIP and/or glucagon receptors are emerging as innovative therapeutic options for diabesity, due to their synergistic effects on glycaemic control, weight loss and metabolic improvement. This review outlines their mechanisms of action, clinical efficacy and safety data from phase 2–3 trials, highlighting the potential of dual and triple agonists to reshape the management of obesity and type 2 diabetes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Agonisti multimodali (doppi e tripli agonisti) nel trattamento della diabesità

  • 期刊论文

  • 发表日期：

    2025年9月10日

查看全文
  • Emmanuele Capobianco,
  • Federica Pippa,
  • Silvia Garelli,
  • Uberto Pagotto

摘要

Multimodal agonists targeting GLP-1, GIP and/or glucagon receptors are emerging as innovative therapeutic options for diabesity, due to their synergistic effects on glycaemic control, weight loss and metabolic improvement. This review outlines their mechanisms of action, clinical efficacy and safety data from phase 2–3 trials, highlighting the potential of dual and triple agonists to reshape the management of obesity and type 2 diabetes.